Total submissions: 10
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory for Molecular Medicine, |
RCV000155316 | SCV000205002 | benign | not specified | 2016-05-21 | criteria provided, single submitter | clinical testing | Arg5143Cys in exon 71 of USH2A: This variant is not expected to have clinical s ignificance because it has been identified in 1.0% (89/8652) of East Asian chrom osomes by the Exome Aggregation Consortium (ExAC, http://exac.broadinstitute.org ; dbSNP rs145771342). |
Eurofins Ntd Llc |
RCV000155316 | SCV000232401 | benign | not specified | 2015-05-13 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000886746 | SCV001030272 | benign | not provided | 2024-02-01 | criteria provided, single submitter | clinical testing | |
Mendelics | RCV000986513 | SCV001135528 | benign | Usher syndrome type 2A | 2019-05-28 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000886746 | SCV001886474 | benign | not provided | 2018-11-27 | criteria provided, single submitter | clinical testing | This variant is associated with the following publications: (PMID: 33090715, 32893482, 31180159, 29625443, 30245029, 28224992, 28488341, 23737954, 24938718, 25356976) |
Fulgent Genetics, |
RCV002492585 | SCV002807544 | likely benign | Usher syndrome type 2A; Retinitis pigmentosa 39 | 2021-09-09 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV003453163 | SCV004182719 | likely benign | Retinitis pigmentosa 39 | 2023-11-04 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV000986513 | SCV004182730 | likely benign | Usher syndrome type 2A | 2023-11-04 | criteria provided, single submitter | clinical testing | |
Dept Of Ophthalmology, |
RCV003888601 | SCV004707181 | likely benign | Retinal dystrophy | 2023-10-01 | criteria provided, single submitter | research | |
Natera, |
RCV000986513 | SCV001453403 | benign | Usher syndrome type 2A | 2019-12-27 | no assertion criteria provided | clinical testing |